It has been recognized for decades that solid tumors can contain regions at very low oxygen concentrations (hypoxia) which do not occur in normal tissues under physiological conditions. During the last four years, we have used multiple technologies to identify and characterize the genomic response of untransformed and transformed mammalian cells to decreased oxygenation (hypoxia) as well as agents such as tirapazamine (TPZ) that become cytotoxic only under oxygen limiting conditions. During the last four years, we have used multiple technologies to identify and characterize the genomic response of untransformed and transformed mammalian cells to decreased oxygenation (hypoxia) as well as agents such as tirapazamine (TPZ) that become cytotoxic only under oxygen limiting conditions. A direct application of gene expression profiling to be used in this study is to identify hypoxia induced genes that code for a secreted products that could be detected in the serum of patients by ELISA assays (Project 4). Such an assay would be a non-invasive, rapid and simple means of assessing tumor hypoxia. One way to take advantage of the decreased oxygenation status of a tumor is to administer a hypoxia activated cytotoxin such as TPZ (Projects 1 & 2). While TPZ has demonstrated great promise in the clinic, the potential to enhance its toxicity could be achieved by increasing the formation of its damaging radical species (Project 1) and/or by inhibiting pathways that restitute the cellular damage induced by TPZ (Project 2). Expression of profiling of squamous cell carcinomas of the head and neck and cervix revealed that two family members, NIP3 (Nineteen K interacting protein) and NIP3L of the pro-apoptotic bcl-2 family are induced under hypoxic conditions (Project 3). These proteins may present a new approach to kill hypoxic cells using molecular cytotoxins that are regulated by low oxygen conditions (Projects 1 & 3). The overall goals of this PPG are to exploit tumor hypoxia therapeutically, and develop molecular markers to detect it. Thus, a common theme of hypoxia or TPZ induced changes in gene and protein expression run throughout the project. Project 1 will investigate the ability to use hypoxia to control the stabilization of proteins to kill cells directly by apoptosis or to metabolize TPZ into its radical damaging species. Project 2 will use yeast expression profiling and homozygous deletion strains to discover genes (and pathways) affecting TPZ sensitivity. Project 3 will use mammalian and yeast gene knockout and expression profiling to understand genes that affect the ability of NIP3 to kill tumor cells. Project 4 will use mammalian expression profiling of hypoxia induced genes that code for secreted proteins as surrogate markers for hypoxia. Few groups could be better positioned to use expression profiling of yeast and mammalian cells to address the mechanism of action of TPZ and pro- apoptotic genes, identify molecular hypoxia markers, and develop novel hypoxia based therapeutics.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA067166-09
Application #
6755019
Study Section
Subcommittee G - Education (NCI)
Program Officer
Stone, Helen B
Project Start
1996-06-15
Project End
2006-06-30
Budget Start
2004-07-01
Budget End
2005-06-30
Support Year
9
Fiscal Year
2004
Total Cost
$1,469,887
Indirect Cost
Name
Stanford University
Department
Radiation-Diagnostic/Oncology
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Vilalta, Marta; Brune, Jourdan; Rafat, Marjan et al. (2018) The role of granulocyte macrophage colony stimulating factor (GM-CSF) in radiation-induced tumor cell migration. Clin Exp Metastasis 35:247-254
Tandon, Neha; Thakkar, Kaushik N; LaGory, Edward L et al. (2018) Generation of Stable Expression Mammalian Cell Lines Using Lentivirus. Bio Protoc 8:
Yang, Zhifen; Zhang, Jing; Jiang, Dadi et al. (2018) A Human Genome-Wide RNAi Screen Reveals Diverse Modulators that Mediate IRE1?-XBP1 Activation. Mol Cancer Res 16:745-753
Benej, Martin; Hong, Xiangqian; Vibhute, Sandip et al. (2018) Papaverine and its derivatives radiosensitize solid tumors by inhibiting mitochondrial metabolism. Proc Natl Acad Sci U S A 115:10756-10761
Rafat, Marjan; Aguilera, Todd A; Vilalta, Marta et al. (2018) Macrophages Promote Circulating Tumor Cell-Mediated Local Recurrence following Radiotherapy in Immunosuppressed Patients. Cancer Res 78:4241-4252
Saiki, Julie P; Cao, Hongbin; Van Wassenhove, Lauren D et al. (2018) Aldehyde dehydrogenase 3A1 activation prevents radiation-induced xerostomia by protecting salivary stem cells from toxic aldehydes. Proc Natl Acad Sci U S A 115:6279-6284
Olcina, Monica M; Kim, Ryan K; Melemenidis, Stavros et al. (2018) The tumour microenvironment links complement system dysregulation and hypoxic signalling?. Br J Radiol :20180069
Castellini, Laura; Moon, Eui Jung; Razorenova, Olga V et al. (2017) KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res 45:3674-3692
VandeKopple, Matthew J; Wu, Jinghai; Baer, Lisa A et al. (2017) Stress-responsive HILPDA is necessary for thermoregulation during fasting. J Endocrinol 235:27-38
Peinado, Héctor; Zhang, Haiying; Matei, Irina R et al. (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17:302-317

Showing the most recent 10 out of 203 publications